Study guide

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex

Key Takeaways Explain This Topic AI

Succinylcholine (1.0-1.5 mg/kg) produces a depolarizing Phase I block characterized by absent fade on Train-of-Four (TOF ratio = 1.0) and lack of post-tetanic potentiation; excessive dosing (>4-5 mg/kg) transitions it to a Phase II desensitization block exhibiting fade and post-tetanic facilitation.

Atypical pseudocholinesterase prolongs succinylcholine and mivacurium paralysis; homozygous atypical variants (EaEa, dibucaine number 20-30) prolong apnea for 4 to 8 hours and require continued mechanical ventilation without anticholinesterase administration.

Succinylcholine triggers lethal hyperkalemic cardiac arrest via proliferated extrajunctional nicotinic receptors (alpha-1-beta-1-delta-gamma and alpha-7 homopentamers) in burns (>24-48h), denervation/spinal cord injury (>24-48h), stroke, prolonged immobilization, and muscular dystrophies.

Cisatracurium undergoes organ-independent Hofmann elimination (77% spontaneous non-enzymatic degradation at pH 7.4 and 37°C) into laudanosine, making it the non-depolarizing NMBA of choice in end-stage renal and hepatic failure.

Sugammadex encapsulates steroidal NMBAs (Rocuronium >> Vecuronium >> Pancuronium) in a 1:1 ratio with zero activity against benzylisoquinolines; routine reversal is dosed at 2 mg/kg (for T2 >= 2), 4 mg/kg (for PTC 1-2), and 16 mg/kg (for immediate rescue 3 minutes post-rocuronium 1.2 mg/kg), and requires 7 days of non-hormonal backup contraception.

Last updated: August 2026

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex

Neuromuscular blocking agents (NMBAs) interrupt synaptic transmission at the neuromuscular junction (NMJ) to facilitate endotracheal intubation, optimize surgical exposure, and prevent patient-ventilator dyssynchrony. Mastery of NMJ receptor kinetics, Phase I versus Phase II depolarizing characteristics, non-depolarizing drug classes, pharmacologic reversal mechanisms, and quantitative objective monitoring is critical for NBCRNA NCE examination success.

1. Neuromuscular Junction Anatomy & Receptor Physiology

Transmission at the NMJ occurs when an action potential depolarizes the motor nerve terminal, opening voltage-gated P/Q-type calcium channels . Influx of C a 2 + Ca^{2+} C a 2 + triggers exocytosis of synaptic vesicles, releasing acetylcholine (ACh) (~5,000–10,000 molecules per vesicle/quantum) into the 20–50 nm synaptic cleft. Acetylcholine rapidly diffuses across the cleft to bind postjunctional nicotinic acetylcholine receptors (nAChRs) concentrated on the crests of junctional folds. Motor Nerve Terminal ───[Ca2+ Influx]───► ACh Exocytosis (5,000-10,000 ACh/vesicle)

  • │
  • ▼
  • Synaptic Cleft ───[Diffuses across 20-50 nm cleft]───► Rapid AChE Hydrolysis
  • │
  • ▼
  • Postjunctional Folds ───[Binds 2 α-subunits simultaneously]───► Na+/Ca2+ Influx & Depolarization
  • Nicotinic Acetylcholine Receptor Subtypes

Receptor Subtype Subunit Composition Anatomical Location Channel Conductance / Open Time Clinical Characteristics

Adult Junctional (Mature) α 1 β 1 δ ϵ α 1 \alpha_1\beta_1\delta\epsilon\alpha_1 α 1 ​ β 1 ​ δϵ α 1 ​ (Two α 1 \alpha_1 α 1 ​ , one β 1 \beta_1 β 1 ​ , one δ \delta δ , one ϵ \epsilon ϵ ) Confined strictly to postjunctional motor endplate High conductance, short open duration (1 ms) Requires two ACh molecules binding simultaneously to both α 1 \alpha_1 α 1 ​ subunits to open channel; normal target of NMBAs

Fetal Extrajunctional (Immature) α 1 β 1 δ γ α 1 \alpha_1\beta_1\delta\gamma\alpha_1 α 1 ​ β 1 ​ δ γ α 1 ​ ( γ \gamma γ substituted for ϵ \epsilon ϵ ) Spread across entire sarcolemma outside NMJ Low conductance, prolonged open duration (4 ms) Proliferates in denervation, burns, immobility; hypersensitive to succinylcholine (massive K + K^+ K + efflux); resistant to non-depolarizers

Neuronal Extrajunctional α 7 \alpha_7 α 7 ​ Homopentamer (Five α 7 \alpha_7 α 7 ​ subunits) Extrasynaptic sarcolemma, nervous system Variable conductance, calcium permeable Upregulated in sepsis, critical illness; stimulated by succinylcholine and choline metabolites; resistant to non-depolarizers

Prejunctional Nicotinic Receptors & Acetylcholine Mobilization

Prejunctional nicotinic receptors ( α 3 β 2 \alpha_3\beta_2 α 3 ​ β 2 ​ and α 7 \alpha_7 α 7 ​ ) reside on the presynaptic nerve terminal. Under high-frequency stimulation (tetanic trains), these receptors act as a positive feedback loop: ACh binding triggers the mobilization of reserve storage vesicles containing acetylcholine from the nerve interior to the active release zones.

Non-depolarizing NMBAs competitively block these prejunctional receptors, impairing ACh mobilization during rapid firing, which manifests clinically as Train-of-Four (TOF) and tetanic fade .

Succinylcholine stimulates prejunctional receptors, maintaining ACh mobilization; hence, Phase I depolarizing block displays no fade .

2. Succinylcholine (Diacetylcholine): Depolarizing Blockade

Succinylcholine consists of two acetylcholine molecules joined by an ester linkage ( C H 3 - C O O - ( C H 2 ) 2 - N + ( C H 3 ) 3 CH_3\text{-}COO\text{-}(CH_2)_2\text{-}N^+(CH_3)_3 C H 3 ​ - COO - ( C H 2 ​ ) 2 ​ - N + ( C H 3 ​ ) 3 ​ ). It is the only clinically used depolarizing NMBA, renowned for its rapid onset (30–60 seconds) and ultra-short duration (5–10 minutes) at standard doses of 1.0 to 1.5 mg/kg IV .

Phase I vs. Phase II Blockade Dynamics

Succinylcholine binds to one or both α 1 \alpha_1 α 1 ​ subunits of the postjunctional nAChR, opening the ion channel and causing prolonged depolarization of the perijunctional endplate. Voltage-gated sodium channels in the perijunctional membrane rapidly inactivate and cannot repolarize, generating a zone of inexcitability that prevents action potential propagation.

Neuromuscular Parameter Phase I Block (Depolarizing) Phase II Block (Desensitization)

Etiology Standard clinical dose (1.0–1.5 mg/kg IV) Repeated/large doses (>4–5 mg/kg), continuous infusion, or atypical pseudocholinesterase

Mechanism Persistent endplate depolarization; perijunctional N a + Na^+ N a + channels inactivated Receptor desensitization, channel conformational closure, intracellular C a 2 + Ca^{2+} C a 2 + overload

Preceded by Fasciculations? Yes (uncoordinated muscle firing upon initial depolarization) No (channels already desensitized)

Train-of-Four (TOF) Pattern No Fade (all 4 twitches uniformly reduced in height; TOF ratio = 1.0) Fade Present (progressive reduction T 4 < T 3 < T 2 < T 1 T_4 < T_3 < T_2 < T_1 T 4 ​ < T 3 ​ < T 2 ​ < T 1 ​ ; TOF ratio < 0.90)

  • Tetanic Stimulation Sustained contraction with no fade Fade present during sustained 50 Hz stimulus
  • Post-Tetanic Potentiation Absent Present (marked post-tetanic facilitation)

Effect of Anticholinesterases Potentiates / Prolongs block (inhibits plasma cholinesterase and adds ACh) Antagonizes / Reverses block (can partially restore transmission)

Antagonism by Precurarization Prevented/antagonized by non-depolarizer pretreatment Additive/synergistic with non-depolarizers

Metabolism, Pseudocholinesterase & The Dibucaine Number

Succinylcholine is metabolized sequentially by pseudocholinesterase (also known as butyrylcholinesterase , plasma cholinesterase , or BChE ), an enzyme synthesized exclusively by the liver and circulating in plasma. Pseudocholinesterase hydrolyzes succinylcholine into succinylmonocholine (which has 1/20th to 1/80th neuromuscular activity) and choline, and subsequently into succinic acid and choline. Succinylcholine → Plasma Cholinesterase Succinylmonocholine + Choline → Plasma Cholinesterase Succinic Acid + Choline \text{Succinylcholine} \xrightarrow{\text{Plasma Cholinesterase}} \text{Succinylmonocholine} + \text{Choline} \xrightarrow{\text{Plasma Cholinesterase}} \text{Succinic Acid} + \text{Choline} Succinylcholine Plasma Cholinesterase ​ Succinylmonocholine + Choline Plasma Cholinesterase ​ Succinic Acid + Choline

Only a minute fraction (~10%) of the injected succinylcholine dose reaches the neuromuscular junction, as 90% is hydrolyzed intravascularly before arriving at the motor endplate. There is zero pseudocholinesterase in the synaptic cleft ; termination of action at the NMJ occurs exclusively by passive diffusion of succinylcholine away from receptors back into the extracellular fluid and plasma.

The Dibucaine Test

Dibucaine is an amide local anesthetic that inhibits normal pseudocholinesterase activity by ~80%, but inhibits atypical genetic variants to a much lesser extent. The Dibucaine Number measures the percentage inhibition of pseudocholinesterase activity by dibucaine under standardized laboratory conditions. It reflects enzyme quality (function) , NOT quantity.

Genotype Allelic Designation Frequency Dibucaine Number Response to Succinylcholine (1 mg/kg)

Homozygous Typical E u E u EuEu E u E u (or N / N N/N N / N ) 96% of population 70 – 80 Normal recovery: 5–10 minutes

Heterozygous Atypical E u E a EuEa E u E a (or N / A N/A N / A ) 1 in 480 (2–4%) 50 – 60 Moderately prolonged: 20–30 minutes

Homozygous Atypical E a E a EaEa E a E a (or A / A A/A A / A ) 1 in 3,200 20 – 30 Profoundly prolonged: 4–8 hours

Fluoride-Resistant Variant E u E f EuEf E u E f / E f E f EfEf E f E f Rare (1 in 150,000) Normal / Low dibucaine; low fluoride number (20–40) Prolonged: 30–180 minutes

Silent Gene Variant E s E s EsEs E s E s 1 in 100,000 0 (no measurable enzyme activity) Profoundly prolonged: 6–8+ hours

Management of Atypical Pseudocholinesterase Paralysis: If a patient fails to recover spontaneous respiration following succinylcholine (or mivacurium), the CRNA must maintain sedation, analgesia, and controlled mechanical ventilation until twitches return spontaneously. Never administer neostigmine during Phase I paralysis , as it inhibits what little functional plasma cholinesterase remains and severely prolongs the blockade. Fresh frozen plasma (FFP) or purified butyrylcholinesterase contains active enzyme but is generally avoided due to transfusion risks.

Acquired Causes of Reduced Pseudocholinesterase Activity

Conditions that reduce circulating pseudocholinesterase levels (producing normal dibucaine number 70–80 but prolonged duration of action of 15–30 minutes):

  • Severe hepatic parenchymal disease (cirrhosis, hepatitis, end-stage liver failure)
  • Advanced pregnancy and immediate postpartum period (20–30% reduction)
  • Severe malnutrition, cachexia, and end-stage malignancy
  • Severe thermal burn injury (>24–48 hours post-injury)
  • Renal failure / uremia

Pharmacologic inhibitors: Organophosphate insecticides , echothiophate eye drops, neostigmine , pyridostigmine , esmolol , metoclopramide , oral contraceptives , monoamine oxidase inhibitors (MAOIs), and cytotoxic chemotherapeutic agents (cyclophosphamide).

Loading diagram... Pathophysiologic Mechanism of Succinylcholine-Induced Hyperkalemic Cardiac Arrest

Succinylcholine-Induced Hyperkalemia & Clinical Contraindications

In healthy patients, succinylcholine administration increases serum potassium by 0.5 mEq/L due to ion flux through mature postjunctional receptors. In patients with proliferated extrajunctional nAChRs , succinylcholine triggers massive, uncontrolled potassium efflux that can raise serum potassium by 3 to 10+ mEq/L , inducing ventricular fibrillation, electromechanical dissociation, and cardiac arrest refractory to standard resuscitation.

High-Risk Clinical Conditions and Safe Windows

High-Risk Clinical Condition Onset of Vulnerability Duration of Absolute Contraindication Pathophysiologic Mechanism

Severe Thermal Burns (>10-20% BSA) 24 to 48 hours post-burn 1 to 2 years (until complete healing and physical rehabilitation) Proliferation of α 1 β 1 δ γ α 1 \alpha_1\beta_1\delta\gamma\alpha_1 α 1 ​ β 1 ​ δ γ α 1 ​ receptors across entire body sarcolemma

Spinal Cord Injury / Paraplegia / Quadriplegia 24 to 48 hours post-injury 6 months to 1 year minimum (often permanent below level of lesion) Denervation supersensitivity and extrajunctional receptor spreading

Stroke / Cerebral Infarction with Hemiplegia 24 to 48 hours post-stroke 6 months or longer (as long as focal motor deficit persists) Upper motor neuron denervation and receptor proliferation

Muscular Dystrophies (Duchenne, Becker) Always Contraindicated Lifetime Contraindication Dystrophin deficiency; triggers massive rhabdomyolysis, hyperkalemia, and cardiac arrest (NOT MH, though clinically mimics it)

Prolonged ICU Immobility / Critical Illness >2 to 3 weeks Duration of ICU stay + rehabilitation Disuse atrophy, critical illness myopathy, and systemic inflammation upregulation

Severe Intra-Abdominal Sepsis / Peritonitis >24 to 48 hours Until sepsis resolves completely Pro-inflammatory cytokine induction of α 7 \alpha_7 α 7 ​ and fetal receptor synthesis

Pre-existing Hyperkalemia ( K + > 5.5 mEq/L K^+ > 5.5\text{ mEq/L} K + > 5.5 mEq/L ) Immediate Until potassium is normalized 0.5 mEq/L baseline rise pushes serum K + K^+ K + into lethal arrhythmogenic threshold

Important Distinction on Precurarization: Administering a "defasciculating" dose of a non-depolarizing NMBA (e.g., rocuronium 0.03 mg/kg) prior to succinylcholine prevents visible muscle fasciculations and reduces postoperative myalgias , but it DOES NOT prevent hyperkalemic cardiac arrest in susceptible denervated or burn patients. Precurarization is never a substitute for avoiding succinylcholine in contraindicated populations.

Other Succinylcholine Adverse Effects & Systemic Toxicities

Cardiovascular Dysrhythmias: Succinylcholine stimulates muscarinic receptors in the cardiac sinus node and parasympathetic ganglia. Produces profound sinus bradycardia, nodal escape rhythms, or asystole , especially upon administration of a second IV dose in adults within 5–10 minutes or following the first dose in pediatric patients . Prevention/Treatment: Pretreatment with atropine (0.02 mg/kg IV) .

Increased Intraocular Pressure (IOP): Increases IOP by 5 to 15 mmHg for 5 to 10 minutes due to tonic contraction of extraocular muscles and choroidal vascular engorgement. Historically contraindicated in open globe lacerations (risk of vitreous extrusion), although clinical risk with deep anesthesia and swift intubation remains debated.

Increased Intragastric Pressure (IGP) & Lower Esophageal Sphincter (LES) Tone: Increases IGP by 15–40 cmH 2 O \text{cmH}_2\text{O} cmH 2 ​ O due to abdominal fasciculations. Concurrently increases LES barrier pressure, maintaining the barrier pressure gradient in patients with intact sphincters. However, in incompetent LES (hiatal hernia, morbid obesity), aspiration risk is heightened.

Increased Intracranial Pressure (ICP): Transiently increases ICP via jugular venous engorgement and muscle spindle afferent stimulation; attenuated by defasciculating non-depolarizer doses and adequate anesthetic depth.

Masseter Muscle Rigidity (MMR): Transient, isolated jaw tightness occurs in ~1% of children. Exaggerated rigidity preventing mouth opening ("jaws of steel") is an early harbinger of Malignant Hyperthermia (MH) in 50% of cases.

Malignant Hyperthermia Trigger: Succinylcholine is a potent triggering agent for MH via defective Ryanodine Receptor-1 ( R Y R 1 RYR1 R Y R 1 ) calcium release channels in skeletal muscle sarcoplasmic reticulum.

3. Non-Depolarizing NMBAs: Aminosteroids vs. Benzylisoquinolines

Non-depolarizing neuromuscular blocking agents act as competitive antagonists at the postjunctional nicotinic acetylcholine receptor. By occupying one or both α 1 \alpha_1 α 1 ​ binding sites, they prevent endogenous acetylcholine from binding, preventing channel opening and endplate depolarization. At high concentrations, they can also cause non-competitive open-channel blockade.

Comparison of Non-Depolarizing Drug Classes

NMBA Agent Class E D 95 ED_{95} E D 95 ​ Dose Intubation Dose Clinical Onset Duration of Action ( 25 % T 1 25\% T_1 25% T 1 ​ ) Primary Elimination Pathway Unique Clinical Considerations

Rocuronium (Zemuron) Aminosteroid 0.3 mg/kg 0.6 mg/kg (RSI: 1.2 mg/kg) 1.5–2.0 min (RSI: 60 s ) 30–40 min (RSI: 60–90 min) Hepatic / Biliary (>70%) , Renal (~20%) Rapid onset makes 1.2 mg/kg an ideal alternative to succinylcholine; reversed rapidly by sugammadex

Vecuronium (Norcuron) Aminosteroid 0.05 mg/kg 0.1 mg/kg 2.5–3.0 min 30–45 min Hepatic / Biliary (40–50%) , Renal (30%), Hepatic metabolism (30%) Active metabolite 3-desacetylvecuronium (50% parent potency) accumulates in renal failure, causing prolonged paralysis

Pancuronium (Pavulon) Aminosteroid 0.07 mg/kg 0.08–0.1 mg/kg 3.5–5.0 min 60–120 min Renal (80%) , Hepatic (15%) Vagolytic effect: blocks cardiac M 2 M_2 M 2 ​ receptors, causing tachycardia and hypertension; contraindicated in CAD/AS

Cisatracurium (Nimbex) Benzylisoquinoline 0.05 mg/kg 0.15–0.2 mg/kg 2.0–3.0 min 40–60 min Hofmann Elimination (77%) , Ester Hydrolysis (23%) 1R-cis, 1'R-cis isomer of atracurium; zero histamine release ; drug of choice in renal and hepatic failure

Atracurium (Tracrium) Benzylisoquinoline 0.25 mg/kg 0.5 mg/kg 2.5–3.5 min 30–45 min Ester Hydrolysis (66%) , Hofmann Elimination (33%) Releases histamine at > 0.4 mg/kg >0.4\text{ mg/kg} > 0.4 mg/kg (hypotension, flushing, bronchospasm); degrades to laudanosine

Mivacurium (Mivacron) Benzylisoquinoline 0.08 mg/kg 0.15–0.2 mg/kg 2.0–2.5 min 15–20 min Plasma Pseudocholinesterase (>95%) Short duration; histamine release with rapid bolus; prolonged by pseudocholinesterase deficiency

Hofmann Elimination Kinetics

Hofmann elimination is a purely non-enzymatic chemical process whereby a quaternary ammonium compound undergoes spontaneous molecular cleavage into a tertiary amine and an alkene at physiologic temperature and pH. Cisatracurium → pH 7.4 , 37 ∘ C Laudanosine + Quaternary Monoacrylate \text{Cisatracurium} \xrightarrow{\text{pH } 7.4,\ 37^\circ\text{C}} \text{Laudanosine} + \text{Quaternary Monoacrylate} Cisatracurium pH 7.4 , 3 7 ∘ C ​ Laudanosine + Quaternary Monoacrylate

Modifiers of Hofmann Elimination:

Acidosis ( p H < 7.35 pH < 7.35 p H < 7.35 ) and Hypothermia ( T < 36 ∘ C T < 36^\circ\text{C} T < 3 6 ∘ C ) slow Hofmann elimination, significantly prolonging cisatracurium duration.

Alkalosis ( p H > 7.45 pH > 7.45 p H > 7.45 ) and Hyperthermia ( T > 38 ∘ C T > 38^\circ\text{C} T > 3 8 ∘ C ) accelerate Hofmann elimination, shortening duration.

Laudanosine Toxicity: A lipophilic tertiary amine metabolite that crosses the blood-brain barrier. At extremely high serum concentrations (following prolonged ICU infusions of atracurium > cisatracurium), laudanosine can stimulate the CNS and induce epileptiform seizure activity. Cisatracurium produces approximately 5 times less laudanosine than atracurium for equivalent neuromuscular block.

4. Pharmacologic Reversal: Anticholinesterases vs. Sugammadex

Recovery from neuromuscular blockade requires restoring functional neuromuscular transmission to ensure uncompromised pharyngeal tone, airway protection, and ventilatory mechanics.

Acetylcholinesterase Inhibitors (Anticholinesterases)

Anticholinesterases inhibit the enzyme acetylcholinesterase (AChE) in the synaptic cleft, preventing the breakdown of endogenous ACh. The resulting accumulation of ACh outcompetes non-depolarizing NMBAs at postjunctional nAChRs, shifting the concentration equilibrium toward channel opening. Anticholinesterase → Inhibits AChE [ ACh ] synaptic ↑ ↑ → Competitive Displacement Displaces Non-Depolarizer from α 1 Subunits \text{Anticholinesterase} \xrightarrow{\text{Inhibits AChE}} [\text{ACh}]_{\text{synaptic}} \uparrow\uparrow \xrightarrow{\text{Competitive Displacement}} \text{Displaces Non-Depolarizer from } \alpha_1 \text{ Subunits} Anticholinesterase Inhibits AChE ​ [ ACh ] synaptic ​ ↑↑ Competitive Displacement ​ Displaces Non-Depolarizer from α 1 ​ Subunits

The Ceiling Effect

Once acetylcholinesterase is 100% inhibited, administering additional anticholinesterase cannot further increase ACh concentrations. Supramaximal dosing causes ACh to accumulate to levels that trigger postjunctional receptor desensitization and open-channel blockade, paradoxically worsening muscle weakness .

Anticholinesterase & Anticholinergic Pairing

Inhibiting AChE increases acetylcholine at both nicotinic and muscarinic receptors . To prevent severe muscarinic toxidrome (bradycardia, asystole, bronchoconstriction, increased airway secretions, miosis, hyperperistalsis), anticholinesterases must always be co-administered with an anticholinergic (antimuscarinic) agent whose pharmacokinetic onset matches the specific anticholinesterase.

Anticholinesterase Agent Structure & BBB Crossing Dose Range Paired Anticholinergic Anticholinergic Dose Onset / Peak Match Clinical Rationale

Neostigmine (Prostigmin) Quaternary amine (Does NOT cross BBB) 0.03 – 0.07 mg/kg (Max 5.0 mg) Glycopyrrolate (Robinul) 0.2 mg per 1.0 mg neostigmine (0.01–0.02 mg/kg) 7–10 minutes (Both peak simultaneously) Gold standard pairing ; matched onset prevents early tachycardia or delayed bradycardia; neither crosses BBB

Edrophonium (Enlon) Quaternary amine (Does NOT cross BBB) 0.5 – 1.0 mg/kg Atropine 0.014 mg per 1.0 mg edrophonium (0.01–0.02 mg/kg) 1–2 minutes (Both rapid onset) Rapid onset match; edrophonium binds electrostatically/reversibly to AChE anionic site

Pyridostigmine (Mestinon) Quaternary amine (Does NOT cross BBB) 0.1 – 0.25 mg/kg Glycopyrrolate 0.05 mg per 1.0 mg pyridostigmine 12–15 minutes (Slow onset, prolonged duration) Used for prolonged reversal or oral treatment of Myasthenia Gravis

Physostigmine (Antilirium) Tertiary amine ( Crosses BBB ) 0.01 – 0.03 mg/kg (0.5–2.0 mg) None (or titrated atropine) N/A 3–5 minutes NOT used for NMBA reversal ; indicated exclusively for Central Anticholinergic Syndrome (atropine/scopolamine toxicity)

Prerequisites for Neostigmine Reversal: Neostigmine should never be administered when there are 0 twitches on TOF . Administration requires a minimum of 2, and preferably 4, tactile twitches on TOF ( T 2 ≥ 2 T_2 \ge 2 T 2 ​ ≥ 2 ). Administering neostigmine during profound block (0–1 twitches) leads to delayed, incomplete reversal and significant postoperative residual neuromuscular weakness.

Loading diagram... Molecular Encapsulation Mechanism of Sugammadex

Sugammadex (Bridion): Cyclodextrin Encapsulation Pharmacology

Sugammadex is a synthetically modified γ \gamma γ -cyclodextrin consisting of 8 repeating glucopyranose units configured in a hollow, truncated cone. The interior cavity is lipophilic, while the exterior surface is rendered hydrophilic by 8 negatively charged carboxylate thio-ether side chains that electrostatically attract the quaternary ammonium groups of steroidal NMBAs.

Mechanism of Action: 1:1 Host-Guest Inclusion Complex

Sugammadex encapsulates free steroidal NMBA molecules in a 1:1 non-covalent stoichiometric complex within plasma. By binding free intravascular rocuronium with extraordinary affinity (association constant K a = 1.79 × 10 7 M − 1 K_a = 1.79 \times 10^7\text{ M}^{-1} K a ​ = 1.79 × 1 0 7 M − 1 ), sugammadex precipitously lowers free plasma rocuronium concentration to zero. This establishes a steep concentration gradient, driving rocuronium molecules off the postjunctional nAChRs back into the plasma, where they are irreversibly encapsulated.

NMBA Selectivity Spectrum Binding Affinity: R o c u r o n i u m ≫ V e c u r o n i u m > P a n c u r o n i u m \text{Binding Affinity: } \mathbf{Rocuronium} \gg \mathbf{Vecuronium} > \mathbf{Pancuronium} Binding Affinity: Rocuronium ≫ Vecuronium > Pancuronium

Benzylisoquinolines: Sugammadex has zero affinity for cisatracurium, atracurium, or mivacurium . It is completely ineffective for benzylisoquinoline reversal.

Succinylcholine: Sugammadex has zero affinity for succinylcholine .

Precise Weight-Based Dosing Guidelines (Actual Body Weight)

Sugammadex dosing must always be calculated using the patient's Actual Body Weight (ABW) , not ideal body weight, to ensure adequate molecular encapsulation of the entire circulating drug volume.

Depth of Neuromuscular Block Objective Monitoring Criteria Sugammadex Dosing (ABW) Expected Recovery Time to TOF Ratio ≥ 0.90 \ge 0.90 ≥ 0.90

Routine / Shallow Block Reappearance of second twitch ( T 2 ≥ 2 T_2 \ge 2 T 2 ​ ≥ 2 on TOF) 2 mg/kg IV 1.5 to 3.0 minutes

Deep Block 0 twitches on TOF, with 1 to 2 Post-Tetanic Counts (PTC 1–2) 4 mg/kg IV 2.5 to 4.0 minutes

Immediate Rescue ("CICO") 3 minutes after high-dose rocuronium (1.2 mg/kg RSI) 16 mg/kg IV 1.5 to 3.0 minutes (reverses rocuronium faster than spontaneous succinylcholine recovery)

Critical Drug Interactions & Clinical Warnings

Oral Contraceptive Interaction (Board Favorite): Sugammadex binds to progesterone and progestin-containing hormonal contraceptives (pills, implants, rings, injections), decreasing their circulating active levels.

Mandatory Patient Instruction: The patient must be informed that receiving sugammadex is equivalent to missing a daily oral contraceptive dose. Patients using hormonal contraceptives must use an additional non-hormonal barrier method (e.g., condoms) for 7 consecutive days following sugammadex administration.

Toremifene Displacement: Toremifene (a selective estrogen receptor modulator used in breast cancer) has high binding affinity for sugammadex and can displace rocuronium or vecuronium from the cyclodextrin cavity, causing recurarization.

Profound Bradycardia & Asystole: Rare cases of severe bradycardia and cardiac arrest have occurred within minutes of sugammadex injection. Continuous ECG monitoring is essential, and atropine must be immediately accessible.

Renal Impairment: Sugammadex and the rocuronium-sugammadex complex are excreted 100% unchanged by the kidneys via glomerular filtration . In severe renal disease ( C r C l < 30 mL/min CrCl < 30\text{ mL/min} C r Cl < 30 mL/min or end-stage renal disease on dialysis), sugammadex is not recommended by the FDA due to prolonged complex retention (up to 7 days), although the complex remains stable and hemodialysis with high-flux filters clears the complex.

Coagulation Effects: Produces transient, minor increases in PT, PTT, and INR for up to 60 minutes after administration without clinically significant increases in postoperative bleeding.

5. Neuromuscular Monitoring Standards & Recovery Criteria

Objective quantitative monitoring is the standard of care to prevent residual neuromuscular blockade—a major cause of postoperative hypoxemia, airway obstruction, microaspiration, and reintubation.

Peripheral Nerve Stimulation Patterns

Train-of-Four (TOF): Four 2-Hz electrical pulses (0.5 seconds apart). TOF Ratio is calculated as the amplitude of the fourth twitch divided by the first twitch ( T 4 / T 1 T_4 / T_1 T 4 ​ / T 1 ​ ).

T 4 T_4 T 4 ​ disappears at ~75% receptor occupancy.

T 3 T_3 T 3 ​ disappears at ~80% receptor occupancy.

T 2 T_2 T 2 ​ disappears at ~85% receptor occupancy.

T 1 T_1 T 1 ​ disappears at ~90–95% receptor occupancy.

Double Burst Stimulation (DBS): Two short 50-Hz tetanic bursts separated by 750 ms ( D B S 3 , 3 DBS_{3,3} D B S 3 , 3 ​ or D B S 3 , 2 DBS_{3,2} D B S 3 , 2 ​ ). Tactile evaluation of fade is significantly easier than standard TOF, detecting residual fade down to TOF ratios of ~0.60.

Post-Tetanic Count (PTC): 50-Hz tetany for 5 seconds, followed by a 3-second pause, then single 1-Hz twitches. Used during profound block (0 twitches on TOF) to quantify how close the patient is to the return of T 1 T_1 T 1 ​ .

Anatomic Monitoring Sites & Muscle Sensitivities

Nerve / Muscle Site Target Muscle Muscle Sensitivity vs Larynx / Pharynx Clinical Role & Monitoring Interpretation

Ulnar Nerve Adductor Pollicis (Thumb adduction) Most Sensitive (Recovers after diaphragm and larynx; matches upper airway / pharyngeal recovery) Gold standard site for emergence and extubation criteria . If TOFR ≥ 0.90 \ge 0.90 ≥ 0.90 at adductor pollicis, the pharynx and airway reflexes have fully recovered.

Facial Nerve Orbicularis Oculi / Corrugator Supercilii Resistant (Onset matches larynx/vocal cords; recovers faster than peripheral muscles) Best site for assessing onset and intubation readiness . Monitoring the facial nerve at emergence is dangerous because it overestimates recovery, risking premature extubation while pharyngeal muscles remain paralyzed.

Posterior Tibial Nerve Flexor Hallucis Brevis (Plantar flexion of great toe) Intermediate Alternative peripheral site when upper extremities are inaccessible.

Extubation Criteria (Quantitative Standard)

Subjective clinical tests (e.g., 5-second head lift, sustained hand grip, inspiratory force > − 25 cmH 2 O > -25\text{ cmH}_2\text{O} > − 25 cmH 2 ​ O , tongue protrusion) can be passed even when 50% to 70% of receptors remain blocked ( T O F R < 0.70 TOFR < 0.70 TOFR < 0.70 ). The mandatory objective standard for safe extubation is a quantitative Train-of-Four Ratio (TOFR) ≥ 0.90 \ge 0.90 ≥ 0.90 (90%) measured at the adductor pollicis muscle .